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In the present work, we examine normal and malignant stage IIIB
cervical tissue by laser induced fluorescence, with 2 different ob-
jectives. (i) Development of the fluorescence spectroscopy tech-
nique as a standard optical method for discrimination of normal
and malignant tissue samples and, (ii) Optimization of the tech-
nique by the method of matching of a sample spectrum with cali-
bration sets of spectra of pathologically certified samples. Laser-
induced fluorescence spectra were measured using samples from
62 subjects at different excitation wavelengths. Principal compo-
nent analysis (PCA) of spectra and intensity ratios of curve-
resolved fluorescence peaks were tested for discrimination. It was
found that PCA of total fluorescence at 325 nm excitation gives
specificity and sensitivity over 95%. Use of calibration sets of spec-
tra of histo-pathologically certified samples combined with PCA
for matching and pass/fail classification of test samples is shown to
have high sensitivity/specificity for routine diagnostic purposes as
well as for possible staging of the disease. Further, the multi-com-
ponent origin of the fluorescence spectra is illustrated by curve re-
solution and fluorescence spectra of separated proteins of tissue
homogenates.
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Key words: laser induced fluorescence; optical diagnosis; principal
component analysis
Cervical Cancer is the second leading cancer in females all over the
world, standing first in many of the developing countries.1,2 Most
patients are diagnosed with cervical cancer through symptoms such as
abnormal vaginal bleeding and vaginal discharge. Investigation by Pap
smear/colposcopy followed by histopathology confirms the diagnosis.
Pap smear is reported to have high false negative (15–40%) rates.3,4
The extraordinary monotony of the work, large volume of smears
in screening applications, inadequate sampling and comparatively
smaller cellular changes being overlooked because of fatigue are all
reasons ascribed to the high rate of false-negative results. At present,
liquid based cytological screening technique ‘‘Thin prep’’ aided by
Pap Net, an automated computer based visualization technique, seems
to have increased the sensitivity of cytological screening. However,
the efficiency of thin prep and Pap net are still under scrutiny.5,6
In case of a suspicious Pap smear or as an independent tech-
nique, colposcopy is performed. The major drawback of colpo-
scopy is usually the lack of experience with a large enough patient
population to become familiar with changes in premalignant and
malignant conditions.7 This often results in failure to recognize
early disease conditions, and in errors like ‘‘past pointing’’, where
the biopsied tissue does not come from the area of abnormality,
but from an adjacent normal epithelium. Both Pap smear and col-
poscopy are prone to errors because of the subjective nature of the
diagnosis.
Optical methods, which are fast, can be automated and can be
made objective by statistical analysis, are therefore being consid-
ered as stand alone/complimentary technique for early detection.
By forming standard calibration sets of pathologically certified
samples in various stages of premalignancy/malignancy, and
determining the statistical probability of how much a test sample
matches with one of these sets, it is possible to have better diagno-
sis. Several groups8–16 have studied fluorescence spectra of normal
and malignant tissue to develop an optical pathology method for
early detection of cancer. The optical method may also serve for
monitoring effectiveness of therapy and early detection of recur-
rence without the need for biopsy.
For routine clinical usage, it is necessary to validate any new
diagnostic method by different groups of investigators as well as
for different ethnic classes. Optimization of the technique, valida-
tion by independent data sets and confirmation of spectral results
by pathology, all will help in establishing the optical method as an
acceptable technique. We have therefore carried out extensive flu-
orescence spectroscopic studies on tissue and tissue homogenate
samples in cervical malignancy. The fluorescence spectra have
been analyzed through multivariate analysis (principal component
analysis) and curve resolution methods.
Our studies have shown that calibration data sets of fluores-
cence spectra with well-defined statistical parameters can be pre-
pared for normal and malignant cervical tissue samples. Any test
sample can then be matched against these standard sets to decide
to which group the sample belongs, with good specificity and sen-
sitivity.
Material and methods
Sample collection and handling
Normal (hysterectomy) and malignant cervical tissue samples
were obtained from 62 subjects attending department of obstetrics
and gynecology, Kasturba hospital, Manipal. The details of the
patient population studied are shown in Table I. After biopsy or
surgical resection the tissue specimens were rinsed, placed in ice
cold physiological saline (pH 5 7.4) and spectroscopic measure-
ments were done immediately. Immediately adjacent part of the
biopsy/surgical sample was fixed in 10% neutral buffered formalin
and subjected to histopathology. Whenever necessary, the tissue
samples were snap frozen in liquid nitrogen and stored at 280C
for later analysis. We have verified that no noticeable changes take
place in spectra for such samples when compared with fresh sam-
ples.
Tissue homogenates were prepared by homogenizing 50 mg of
fresh wet tissue in 200 ll of 10 mM Tris-EDTA buffer (pH 7.4) in
a homogenizer (IKA-WERKE GMBH & Co. Germany Ultra Tur-
rax T8) for 5 min. The homogenate was centrifuged and superna-
tant was collected. Twenty microliters of a suitably diluted super-
natant was injected into an high performance liquid chromatogra-
phy laser induced fluorescence (HPLC) system to separate the
component proteins.
HPLC-LIF – tissue homogenate
The component proteins of the tissue homogenate were sepa-
rated in a HP1100 HPLC system, using narrow-bore Vydac
biphenyl column (Model 219TP52). The details of this set up are
discussed elsewhere.17 The effluent was passed through a quartz
capillary flow cell (75 lm id, 300 lm od) where it was illuminated
with a focused 257 nm beam from a frequency-doubled Argon ion
laser (Coherent Innova Model FreD 90C). The fluorescence was
collected at 90 on 1 side and measured using a JY - DH10 double slit
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monochromator, Photo multiplier (Hamamatsu R750) and lock-in
amplifier (EG&G Model No DSP 7265). Simultaneously the fluo-
rescence spectra of eluted proteins were also recorded from the
opposite side using a Spectra Pro 150 spectrograph coupled to a
Princeton CCD (Roper Scientific, model RTE/CCD-128-HB).
Tissue fluorescence spectroscopy
Tissue samples were excited with an Nd-YAG- MOPO-FDO
laser system (Spectra Physics Laser, USA, model PRO 230). Fluo-
rescence spectra were recorded on an Acton (Spectra-Pro 150)
spectrometer (slit width 200 lm, band pass 2.0 nm) equipped with
a 300 g/mm grating, blazed for 300 nm. Dispersed spectra were
accumulated with an Andor ICCD (Andor Technology, Northern
Ireland DH-501-25F-01), gated with an SRS DG 535 delay gener-
ator. The DG 535 was triggered with the Q-Switch Advance signal
from the laser. The details of the set up are discussed elsewhere.18
Each tissue specimen was mounted on a quartz plate and kept
moist with the physiologic saline throughout the experiment. A
conventional fiber optic probe was used to deliver the laser light
and to collect the fluorescence. The probe consists of a 7-fiber as-
sembly, with a central fiber to deliver the laser light and the sur-
rounding 6 fibers to collect the fluorescence. The individual fibers
(Thorlabs FG 200-UEP Fiber type) were 240 lm diameter with
numerical aperture of 0.25. Two to 5 sites were studied on each
tissue sample at any given excitation wavelength. No spectral
changes were observed for exposures of up to even 2 hr with the
pulsed laser radiation, as had been reported by others also.19 All
spectra were recorded by accumulating 500 pulses, and thus took
less than a minute at the 10 Hz repetition rate.
Spectral data processing
The fluorescence spectra were corrected for background by a
multiple point polynomial fit to remove the background. The re-
sultant spectra were analyzed by the method of principal com-
ponent analysis (PCA) and curve resolution techniques using
GRAMS 32 and PLS Plus/IQ programs (Galactic Industries corpo-
ration, USA). Trial runs of PCA showed that 5 factors contribute to
more than 98% of the total variance of the set of 218 spectra, and
therefore, only 6 factors were used in all further spectral analysis.
PCA was done by 2 different approaches. In the first approach,
the 218 spectra from normal, malignant and blind data were com-
bined together and PCA was done with 6 factors (Principal Com-
ponents), and their scores for each sample were evaluated. The
scores were then used for discrimination between the normal and
malignant tissue types. In the second method, 20 randomly
selected spectra of pathologically certified normal/ malignant sam-
ples were used to form calibration sets. All spectra (including the
members of the calibration set) were then matched (members of
the calibration set retrospectively by rotating out one at a time and
others prospectively) with the calibration sets to see to which set
they belong. The second method obviously will be a better choice
for situations where different stages have to be identified like CIN
I, CIN II, etc. Comparison with calibration sets of each class can
be then done for better diagnosis.
Spectra were also resolved into component bands by standard
curve resolution techniques20 to identify variations in fluorescence
between normal and malignant samples, arising from changes in
tissue components. Intensity ratio changes of pairs of resolved
peaks were also tested for discrimination purposes.
Results
A total of about 1,000 spectra were measured on tissue speci-
mens taken from 62 subjects with varying cervical pathology (16
Normal, 4 carcinoma in situ and 42 cancerous) at 4 excitation
wavelengths, 275, 325, 375 and 425 nm. Figure 1 shows typical
fluorescence spectra of normal and malignant cervical tissue on
excitation at the earlier mentioned wave lengths. Since 325 nm ex-
citation showed maximum difference between normal and malig-
nant samples, excitation at 305–335 nm (at 10 nm intervals) was
studied and again 325 nm excitation was found to be optimum.
For a given pathologically certified normal or malignant sample,
site-to-site variations were found to be only nominal as shown in
Figure 2.
There are several statistical parameters like scores of factors,
spectral residuals and Mahalanobis Distance21,22 available for de-
cision-making in PCA. As already mentioned, in the present work,
5 factors contributed to more than 98% of the total variance in the
spectrum and the contributions of these factors to each spectrum
give the scores for that spectrum. Samples belonging to a given
class will have score values very close to each other, at least for
the major factors. A scatter plot of the scores will thus serve as in-
dicator of the sample type. The mean value and standard deviation
of the scores of the calibration sets can then be used for decision-
making.
When the scores of the significant factors for any spectrum are
known the spectrum can be simulated and the spectral residual
given by Rs 5 R
p
i 5 1(So
i 2 Ss
i)2 can be calculated as the sum of
the squares of the differences between observed and simulated
intensities across the p spectral points. Obviously, if the spectrum
of a sample does not belong to a particular class, the spectral resid-
ual for that sample will be very high. Once again, the mean value
and standard deviation of the spectral residuals of the calibration
set can be used as statistical parameters for deciding whether a test
sample belongs to that class or not.
The Mahalanobis Distance, a well-known statistical parameter,
is defined for the present system by the equation D25 (Sun) M
21
(Sun)
1 where Sun is the vector of scores and sum of squared spec-
tral residual for a given unknown sample. M is the Mahalanobis
matrix, given by M 5 S1S/ (n2 1) where S is the n by f matrix of
the standard calibration set of n standards, and f, their respective
scores.
In the first method of PCA, all the 218 spectra obtained with
325 nm excitation were combined together, and the scores were
evaluated with 6 factors. Figure 3 shows the scatter plot of the
scores for factor 1 (contribution to spectral variance 68%) against
sample number. In this plot, spectrum numbers 1–40 are from
pathologically certified normal, and 41–75 from similar FIGO
stage III cancer tissue specimens. The rest are test samples where
the histopathology results were obtained after the spectroscopy
analysis.
It is evident that for pathologically certified normal and malig-
nant samples there is complete separation as clusters for scores of
factor 1, indicating 100% sensitivity and specificity as shown on
the left panel of the Figure 3. The results for the ‘‘blind’’ test sam-
ples are shown on the right panel of the figure. In the blind set all
malignant stage IIIB tissue spectra have scores of that class except
5 spectra coming from 3 specimens indicated in boxes, which
come in the range of normal category. The reasons for this are dis-
cussed later. No normal tissue specimens showed any overlapping
with the scores of the malignant samples.
For the second method of PCA, in the present study, we have
reasonably large number of samples for normal and stage III
malignancy only. These 2 groups were therefore used to form cali-
bration sets of 20 randomly selected spectra of each class and all
samples were matched against these 2 sets. The results are shown
TABLE I – SUMMARY OF PATIENT POPULATION STUDIED FOR
FLUORESCENCE SPECTROSCOPY TECHNIQUE
Number of
subjects
studied
Number of
sites
studied
Mean age
in years6 SD
Normal 16 060 38 6 6
FIGO stage III cancer 42 143 52 6 8
Carcinoma in situ 04 015 32 6 5
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in Table II. Here, all the 218 spectra were matched against a cali-
bration set of 20 spectra selected randomly from the pathologi-
cally certified normal sample spectra. The scores, spectral resid-
uals, and Mahalanobis distances were used as parameters for
matching. If a test sample matches in all 3 parameters, the range
of values for the calibration set is classified as ‘‘PASSED,’’ other-
wise as ‘‘FAILED’’.
It is well recognized that the total fluorescence of tissue arises
from several biochemical species.23 Generally the total fluorescence
is assigned as arising from proteins with aromatic amino acids, col-
lagen, NADH, flavins etc. Few attempts24,25 have been made for
separating the total fluorescence into those of individual compo-
nents. We have studied this problem through curve resolution.
The fluorescence spectra for excitation at 275, 325 and 375 nm
are quite asymmetric on a wavenumber scale and also shows weak
shoulders, indicating more than 1 band in each case. For 275 nm,
where protein fluorescence is dominant, curve fitting gave a strong
peak at 345 nm with several weak peaks at shorter wavelengths.
Also a medium intensity band was seen at around 390 nm. These
bands have to come from different proteins (345 and below) and
some collagen (390 nm) though collagen has only weak absorption
at 275 nm. Similarly, 375 nm excitation gives 2 peaks for malig-
nant tissue, 1 around 440 nm (bound NADH) and the other around
470 nm (free NADH). Excitation at 425 nm on the other hand
gives only 1 peak at 500 nm for both normal and malignant sam-
ples and this can be from flavins. Figure 4 shows the curve fitting
for 325 nm excitation. This shows the presence of about 4 bands
so that it cannot be simply assigned to collagen and NADH (Free/
Bound). However, the stronger peaks in these spectra correspond
FIGURE 2 – Fluorescence spectra measured at different sites of
pathologically certified Normal (a) and Malignant (b) tissue samples
at 325 nm excitation.
FIGURE 3 – Scatter plot of scores of factor 1 for 218 spectra. 1–40,
Normal; 41–75, Malignant. On the right side, all spectra in any 1 box
correspond to different sites on 1 sample. (Hollow triangles) patholog-
ically certified Normal; (Hollow circles) pathologically certified Ma-
lignant; (Filled triangles) test samples – Normal; (Filled Circles) test
samples – Malignant; (Hollow stars) CIS.
FIGURE 1 – Typical fluorescence spectra of
normal and malignant cervical tissue samples
at 4 excitation wave lengths: (a) 275; (b) 325;
(c) 375 nm; (d) 425 nm. All spectra normal-
ized to Peak intensity 5 1. (——) Normal;
(- - - -) Malignant.
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to collagen and NADH.26 The intensity ratios of these peaks for
normal and malignant samples are plotted in Figure 5. It can be
seen that there is substantial difference in the ratio of concentra-
tion of collagen to NADH in malignancy, as shown by earlier
workers also.25
It is well known that Hemoglobin has strong absorption in this
region, peaking at around 420 nm. The dip in the fluorescence
spectrum can thus be attributed to this Hb absorption. However,
while this is likely for in vivo observations, in our studies there is
very little chance for Hb absorption for the following reason. Since
all samples were collected in saline and removed from this medium
before taking spectrum, any blood originally present will mostly be
removed from the sample. Also if the dip was from Hb absorption,
it should have been more in malignant samples due to possible
increase in Hb content because of angiogenesis. Further, time-
delayed spectroscopy18 shows that the fluorescence in this region
comes from 2 major bands with entirely different time evolution.
The presence of several molecular species under a general cate-
gory like proteins becomes evident from our results on tissue
homogenates. Figure 6 shows the chromatograms of tissue homo-
genates from normal and malignant tissues. These were recorded
by detecting the fluorescence at 340 nm ‘‘on-the-fly’’17; and show
the concentrations of different proteins in the homogenate. It can
be seen that the total protein spectrum observed at 275 nm
(Fig. 1a) excitation comes from overlapping spectra of several
proteins. It is clear that there are noticeable differences in the
spectra, a fact which is not obvious from the total spectrum,
because of the overlapping.
Discussion
Immunological, biochemical and other techniques like fluores-
cence imaging are in use for identification and classification of var-
ious stages of a cancer. However, these methods are time consum-
ing and are often expensive. Recently fluorescence based analysis
of cellular constituents have been investigated.27 In the present
study, we have analyzed laser-induced fluorescence of cervical
cancer tissues compared to its normal counterpart. We have further
refined the data using statistical analysis and checked test samples
to evaluate its usefulness in diagnosis. Our major findings are (i)
excitation at 325 nm gives better discrimination between normal
and malignant tissues. (ii) Variation in fluorescence spectra at dif-
ferent sites of the tumor or normal tissue specimen is minimal
when pathologically certified biopsy samples are studied. Site-to-
site variations may be observed in malignant tissue specimens
taken through visual examination. (iii) Matching of a test sample to
calibration sets can provide objective, reliable diagnosis.
In many earlier fluorescence and Raman techniques28,29 when a
number of spectra are recorded from different sites of 1 tissue
TABLE II – MATCH/MISMATCH TEST BY PCA WITH CALIBRATION SET OF 20 RANDOMLY SELECTED,
PATHOLOGICALLY CERTIFIED NORMAL TISSUE SPECTRA
Match Mahalanobis distance Limit test1 Spectral residual
Spectra 1 Yes 0.20525 PASS (PPP) 0.36076
Spectra 2 Yes 0.69301 PASS (PPP) 0.95297
Spectra 3–40 Yes – PASS (PPP) –
Spectra 41 No 28.88197 FAIL (FFF) 19.31267
Spectra 42 No 25.74399 FAIL (FFF) 17.31778
Spectra 43–75 No – FAIL (FFF) –
Spectra 76 Yes 1.20861 PASS (PPP) 1.27771
Spectra 77 Yes 2.78025 PASS (P?P) 2.35817
Spectra 78–95 Yes – PASS (PPP) –
Spectra 96 No 3.72024 FAIL (F?F) 2.99056
Spectra 97–203 No – – –
Spectra 1092 Yes 1.76363 PASS (PPP) 1.61630
Spectra 1182 Yes 1.45786 PASS (PPP) 1.44354
Spectra 1192 Yes 0.78751 PASS (PPP) 0.90153
Spectra 1202 Yes 0.57438 PASS (PPP) 0.11071
Spectra 1222 Yes 0.56065 PASS (PPP) 0.51257
Spectra 1922 Yes 2.25837 PASS (PPP) 2.01522
Spectra 1–40 are pathologically classified as normal; spectra 41–75 pathologically classified as malig-
nant; 76–95 test-normal sample; 96–203 test-malignant spectra of visually aided biopsy samples; 204–
218 are spectra from carcinoma in situ samples.
1PPP – Mahalanobis distance, spectral residual, score.–2Abnormal blind samples of Figure 3. See text
for details.
FIGURE 4 – Typical curve-fitted spectrum at 325 nm Excitation. (a)
Normal; (b) Malignant. (——) Observed spectrum; (- - - -) fitted
curves.
FIGURE 5 – Intensity ratio of resolved peaks (a) and (d) of Figure 4.
(Hollow circles) pathologically certified normal tissue spectra; (Filled
circles) pathologically certified malignant tissue spectra.
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sample, the mean of these is taken as representative of that sample
for further data processing and evaluation. In the present work, the
218 spectra obtained from 62 samples are treated as independent
data. This, we believe, is a better approach for the following rea-
sons. First, in epithelial cancers, like carcinoma of the cervical
mucosa, (before it has penetrated the underlying tissue), often a
tissue specimen can have normal and anaplastic regions adjacent
to each other.30 The pathologist examines several sites on a biopsy
sample and even if 1 site shows as abnormal, sample is considered
as abnormal. Secondly, for in vivo applications in screening, surgi-
cal boundary demarcation and optically guided biopsy it is neces-
sary to identify the exact site where malignancy begins or termi-
nates. The variations in the spectra from site to site will be the
deciding factor in these situations and they have to be treated inde-
pendently. Thirdly, in epithelial cancers the abnormal proliferation
starts near the basal lamina and advances into the epithelial region,
and eventually in the invasive stage penetrates in the connective
tissue region. We have shown31 by Raman spectroscopy that in
biopsied tissue samples of oral cancer, the sub-epithelial region
showed very similar spectra for normal and malignant samples,
and only the epithelial spectra discriminated between the 2 very
well. This indicates that unless one is sure which region (epithe-
lial, sub-epithelial or connective tissue) one is looking at in a ma-
lignant sample there can be both normal and malignant types of
spectra from adjacent sections of the same sample. It is thus clear
that when there is no a priory information available for a sample it
is necessary to examine many sites on the sample and treat each
site as different.
In Figure 3, we have shown the scores for all the spectra. For
pathologically certified normal and malignant samples there is
complete separation between the clusters for the 2 classes of sam-
ples indicating 100% sensitivity and specificity. In the results for
the test samples shown on the right panel of the figure, an overlap-
ping with the normal class can be seen in 5 spectra from the malig-
nant test samples indicated in the boxes. This is due to the pres-
ence of normal tissue sections in the biopsy and it has been further
confirmed with the histopathological analysis. This possibility of
normal tissue contamination in biopsy sections obtained through
visual identification is very important when analyzing the precan-
cerous stages, where the number of transformed cells can be quite
small. Our results on precancerous tissue, shown in the extreme
right panel of Figure 3, indicate a distribution of spectral scores in
both normal and malignant categories. From these results it is evi-
dent that a sample should be screened at several sites, and each
site should be treated independently. The sample should be cate-
gorized as malignant even if a single site shows malignant spectral
features. This is further supported by the result that there is abso-
lutely no overlapping for the normal specimens. The normal tissue
contamination also raises concern over the routine biopsy proce-
dure aided only by visual techniques. In this case, we feel that a
biopsy guided by fluorescence spectroscopy can yield more accu-
rate diagnosis. Further, the technique is also helpful in demarka-
tion of the surgical area during the tumor removal. It is clear that
any spectral studies either in vivo or in vitro (biopsy) should cover
as many sites as possible during a routine screening to minimize
the chances of a premalignant/malignant condition being classified
as normal. The fluorescence technique can compliment visual
judgment for biopsy even in inexperienced hands.
It may be possible that if there are many groups of data set (e.g.
HPV infection, inflammation, CIN I, CIN II etc) the scores for 1
or more factors may still group in different clusters, and a correct
diagnosis may be possible when all the data are processed to-
gether. However, it is more likely that the scores may overlap
because of slowly varying spectral characteristics and may cover a
FIGURE 6 – HPLC peaks from
tissue homogenates. (a) Normal.
(b) Malignant. Vydac Narrow Bore
Biphenyl (Model 219TP52) Col-
umn. Gradient – 80% H2O, 20%
Acetonitrile at time 5 0 min. And
20% H2O, 80% Acetonitrile at time
5 60 min. The fluorescence spectra
of 2 peaks a and b which are elut-
ing at the same time are shown as
insets in the corresponding figure.
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wide range. Clear discrimination may then become difficult using
only scores of factors.
When calibration sets are available for the different stages (e.g.
pathologically classified sets of CINI, CINII etc.) of the disease, a
PCA can be done with each set. Any new sample can then be
matched against each calibration set and a more reliable classifica-
tion may be achieved by identifying the set to which the sample
matches best. It is seen from Table II, that all normal spectra
(including the pathologically certified, but not included in the cali-
bration set, as well as test spectra) pass the match/mismatch test.
Out of 143 spectra from 42 malignant samples, 6 spectra pass the
limit test as normal. These correspond to those that fell into the
factor 1 score region of normal samples in Figure 3. The other
spectra from these tissue samples classified as ‘‘fail,’’ that is, ma-
lignant. Since a sample has to be considered as malignant even if
1 site turns out to be malignant, this type of matching leads to
100% sensitivity and specificity!
The pass/fail test with a calibration set of 20 randomly selected
spectra from the malignant group gave all normal as ‘‘fail’’ giving
a specificity of 100%. Out of 143 malignant sample spectra, 113
classified as ‘‘pass,’’ and 20 classified as ‘‘possible,’’ meaning
they match 2 out of the 3 parameters very well and the third pa-
rameter to some extent. Since the ‘‘possible’’ failed to match the
normal calibration set, they can be classified as malignant. Ten
samples failed to match with the malignant set. Out of the 10, 6
are those mentioned earlier which matched with the normal set.
The remaining misclassification may arise from several reasons
like the sites not corresponding to Stage III B. This is supported
by the fact that these samples also failed to match the normal cali-
bration set.
The results of the curve resolution studies, and ratio of intensity
plots show that this method could also possibly be used for dis-
crimination between normal and stage III malignancies. For exam-
ple, the intensity ratios of the resolved bands are plotted against
sample number in Figure 5. Out of the possible combinations of
bands, only those common to both normal and malignant tissues
are shown in this figure. Earlier workers have generally assigned
the 2 observed broad peaks at about 390 and 450 nm to collagen
and NADH, respectively. Changes in relative intensities have been
attributed to thickening of epithelial layer, loss of collagen and
increase in NADH level in malignancy. However, curve resolution
studies show that there are 4 peaks in this region (Fig. 4) indicat-
ing other components in addition to collagen and NADH. Also the
changes in peak positions and intensities of these bands between
normal and malignant samples show that they exist in very differ-
ent environmental situations, leading to different radiative and
nonradiative processes. Figure 5 (peak a: peak d) showing the col-
lagen: NADH ratio seems to give better discrimination between
normal and Stage III samples compared to ratio of other peaks.
However, in general, the discrimination here is inferior to that
observed with PCA.
We have carried out similar PCA studies with the fluorescence
spectra excited by 275 nm also since the spectra showed some dif-
ferences between normal and malignant samples. However, the
sensitivity and specificity were not as good in this case as for
325 nm excitation.
The high performance liquid chromatography laser induced flu-
orescence (HPLC-LIF) result of tissue homogenates shows the dif-
ferential expression of several proteins in malignancy, a result of
increased rate of cell proliferation and metabolism. The interesting
result here is that even the proteins eluting at the same time (peaks
a and b of Fig. 6) seem to be different in structure as seen from
their fluorescence spectra shown as inset in each case. This may
be because of presence of an altered protein in malignancy, and
could serve as a possible tumor marker. The sensitivity of HPLC-
LIF is very high and we have shown that our system can detect
sub-femtomole quantities as of now, and this sensitivity can fur-
ther be increased 2–3 orders of magnitude if required.17 It is thus
quite likely that this method of protein profile analysis can be used
with great advantage for early detection and staging of cervical
cancer with tissue homogenate, cell lysates (Pap smear) and cervi-
cal wash samples.
In conclusion, we have shown that PCA based multivariate
analysis with different calibration sets corresponding to different
stages of disease can be used with higher sensitivity and specific-
ity for predicting a new sample. Also spectral results closely
match the pathology results even when there is no prior informa-
tion, indicating fluorescence spectroscopy method can be used for
successful location of biopsy sites as a stand-alone technique or
complementary method to colposcopy. Curve resolution studies
have indicated the contribution of fluorescence species other than
collagen and NADH at 325 nm excitation. In the same manner,
spectra of chromatographically separated proteins from tissue ho-
mogenates have been shown to have very different spectra, even
though the tissue fluorescence showed more or less a single fluo-
rescence peak in this region. It should be emphasized that the
spectroscopic evaluation of samples takes very little time [few
minutes] and could provide an objective, fast method for rapid
screening and diagnosis in cervical cancer.
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